Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 675)
Posted On: 01/08/2024 6:10:07 PM
Post# of 155122
Posted By: ohm20
Re: docj #140446
With the results from the Long Covid phase 2 trial, the lack of viable treatments, the huge number of patients willing to jump in a trial and the relatively low cost of a trial (biomarkers, physical and mental acuity tests and questionnaires) this should be pursued. It's a much larger market base then immune activation in HIV and the profit once approved could fund that trial and so much more.

Being a phase 3 trial rather than a phase 2 it would be larger and therefore more expensive than phase 2 immune activation in HIV so it could come down to being risk adverse. It could also be the FDA being dissuasive of any other trial but IA in HIV.













(13)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site